These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

529 related items for PubMed ID: 16052440

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Cannabis; adverse effects from an oromucosal spray.
    Scully C.
    Br Dent J; 2007 Sep 22; 203(6):E12; discussion 336-7. PubMed ID: 17703180
    [Abstract] [Full Text] [Related]

  • 25. Are cannabinoids effective in multiple sclerosis?
    Meza R, Peña J, García K, Corsi O, Rada G.
    Medwave; 2017 Mar 10; 17(Suppl1):e6865. PubMed ID: 28306712
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis.
    Meinck HM, Schönle PW, Conrad B.
    J Neurol; 1989 Feb 10; 236(2):120-2. PubMed ID: 2709054
    [Abstract] [Full Text] [Related]

  • 30. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
    Collin C, Davies P, Mutiboko IK, Ratcliffe S, Sativex Spasticity in MS Study Group.
    Eur J Neurol; 2007 Mar 10; 14(3):290-6. PubMed ID: 17355549
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Medical cannabis: the opportunity versus the temptation].
    Naftali T.
    Harefuah; 2011 Dec 10; 150(12):911-2, 935. PubMed ID: 22352284
    [Abstract] [Full Text] [Related]

  • 33. Examining the roles of cannabinoids in pain and other therapeutic indications: a review.
    Turcotte D, Le Dorze JA, Esfahani F, Frost E, Gomori A, Namaka M.
    Expert Opin Pharmacother; 2010 Jan 10; 11(1):17-31. PubMed ID: 20001426
    [Abstract] [Full Text] [Related]

  • 34. [Cannabinoids in multiple sclerosis -- therapeutically reasonable?].
    Mauch E.
    Fortschr Neurol Psychiatr; 2005 Dec 10; 73(12):713-4. PubMed ID: 16355313
    [No Abstract] [Full Text] [Related]

  • 35. Overview of MS spasticity.
    Pozzilli C.
    Eur Neurol; 2014 Dec 10; 71 Suppl 1():1-3. PubMed ID: 24457845
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
    Barnes MP.
    Expert Opin Pharmacother; 2006 Apr 10; 7(5):607-15. PubMed ID: 16553576
    [Abstract] [Full Text] [Related]

  • 38. [Therapy of pain syndromes in multiple sclerosis -- an overview with evidence-based recommendations].
    Pöllmann W, Feneberg W, Steinbrecher A, Haupts MR, Henze T.
    Fortschr Neurol Psychiatr; 2005 May 10; 73(5):268-85. PubMed ID: 15880305
    [Abstract] [Full Text] [Related]

  • 39. Symptom management.
    O'Connor P.
    Adv Neurol; 2006 May 10; 98():227-55. PubMed ID: 16400837
    [No Abstract] [Full Text] [Related]

  • 40. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis.
    Wade DT, Makela PM, House H, Bateman C, Robson P.
    Mult Scler; 2006 Oct 10; 12(5):639-45. PubMed ID: 17086911
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.